Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.33 |
| ▸ | RELA | Q04206 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7115392 | 1.00 | CA2 (0.44) | CA2HTR1DHTR1ANFKB1NFKB2 | |
| SCHEMBL7114684 | 0.80 | KDM4E (0.38) | HTR1DHTR1ANFKB1NFKB2RELA | |
| SCHEMBL7114678 | 0.80 | KDM4E (0.38) | HTR1DHTR1ANFKB1NFKB2RELA | |
| SCHEMBL4823723 | 0.75 | CA2 (0.75) | CA2HTR1DHTR1A | |
| SCHEMBL6346222 | 0.75 | CA2 (0.75) | CA2HTR1DHTR1A | |
| SCHEMBL6629103 | 0.74 | CA2 (0.44) | CA2HTR1DHTR1AHTR6 | |
| SCHEMBL4622281 | 0.74 | CA2 (0.44) | CA2HTR1DHTR1AHTR6 | |
| SCHEMBL7313874 | 0.73 | NFKB1 (0.46) | HTR1DHTR1ANFKB1NFKB2RELA | |
| SCHEMBL7116097 | 0.73 | NFKB1 (0.57) | NFKB1NFKB2RELADRD2DRD3 | |
| SCHEMBL7116091 | 0.73 | NFKB1 (0.57) | NFKB1NFKB2RELADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353670-A2 | USE OF CHROMANES | Bayer Aktiengesellschaft (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-20020177616-A1 | Use of chromans | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-28 | — | — | US | disclosed |
| WO-2002055078-A2 | USE OF CHROMANES FOR TREATING PARKINSON'S DISEASE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-18 | — | — | WO | disclosed |
| EP-0749970-B1 | Benzisothiazolyl-substituted aminomethylchroman derivatives | BAYER AG (DE) | 2001-01-17 | — | — | EP | disclosed |
| US-5942529-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-24 | — | — | US | disclosed |
| EP-0749970-A1 | Benzisothiazolyl-substituted aminomethylchroman derivatives | BAYER AG (DE) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177616-A1 | Use of chromans | SNCA, PARK7, COMT | CA2 197/4885HTR1D 10/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.